0001209191-20-002271.txt : 20200107
0001209191-20-002271.hdr.sgml : 20200107
20200107162824
ACCESSION NUMBER: 0001209191-20-002271
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200103
FILED AS OF DATE: 20200107
DATE AS OF CHANGE: 20200107
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bodick Neil
CENTRAL INDEX KEY: 0001598099
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36287
FILM NUMBER: 20513607
MAIL ADDRESS:
STREET 1: C/O FLEXION THERAPEUTICS, INC.
STREET 2: 10 MALL ROAD, SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Flexion Therapeutics Inc
CENTRAL INDEX KEY: 0001419600
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
BUSINESS PHONE: (781) 305-7777
MAIL ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-03
1
0001419600
Flexion Therapeutics Inc
FLXN
0001598099
Bodick Neil
C/O FLEXION THERAPEUTICS, INC.
10 MALL ROAD, SUITE 301
BURLINGTON
MA
01803
0
1
0
0
Chief Scientific Officer
Common Stock
2020-01-03
4
S
0
3851
D
100153
D
Common Stock
1000
I
By spouse
Common Stock
388683
I
By Versant Development Fund III, LLC
Sale of shares of common stock to cover tax withholding obligations associated with the vesting of restricted stock unit awards granted to the Reporting Person on February 1, 2018 and March 1, 2019.
The shares were sold at a range of prices between $19.75 and $19.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
/s/ Mark S. Levine, Attorney-in-Fact
2020-01-07